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Sanguinarine (SNG), a benzophenanthridine alkaloid, has displayed various anticancer
abilities in several vivo and in vitro studies. However, the anticancer potential of SNG
is yet to be established in multiple myeloma (MM), a mostly incurable malignancy of
plasma cells. In this study, we aimed to investigate the potential anti-proliferative and
pro-apoptotic activities of SNG in a panel of MM cell lines (U266, IM9, MM1S, and
RPMI-8226). SNG treatment of MM cells resulted in a dose-dependent decrease in cell
viability through mitochondrial membrane potential loss and activation of caspase 3, 9,
and cleavage of PARP. Pre-treatment of MM cells with a universal caspase inhibitor,
Z-VAD-FMK, prevented SNG mediated loss of cell viability, apoptosis, and caspase
activation, confirming that SNG-mediated apoptosis is caspase-dependent. The SNG-
mediated apoptosis appears to be resulted from suppression of the constitutively active
STAT3 with a concomitant increase in expression of protein tyrosine phosphatase (SHP-
1). SNG treatment of MM cells leads to down-regulation of the anti-apoptotic proteins
including cyclin D, Bcl-2, Bclxl, and XIAP. In addition, it also upregulates pro-apoptotic
protein, Bax. SNG mediated cellular DNA damage in MM cell lines by induction of
oxidative stress through the generation of reactive oxygen species and depletion of
glutathione. Finally, the subtoxic concentration of SNG enhanced the cytotoxic effects
of anticancer drugs bortezomib (BTZ) by suppressing the viability of MM cells via
induction of caspase-mediated apoptosis. Altogether our findings demonstrate that SNG
induces mitochondrial and caspase-dependent apoptosis, generates oxidative stress,
and suppresses MM cell lines proliferation. In addition, co-treatment of MM cell lines
with sub-toxic doses of SNG and BTZ potentiated the cytotoxic activity. These results
would suggest that SNG could be developed into therapeutic agent either alone or in
combination with other anticancer drugs in MM.
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INTRODUCTION
Multiple myeloma (MM) is a hematological malignancy
characterized by the proliferation of clonal plasma cells
in the bone marrow (BM) accompanied by secretion of
monoclonal immunoglobulin (1). As standard chemotherapy
and hematopoietic stem-cell transplantation still do not offer
a cure for patients, alternative strategies are required for
therapeutic intervention (1).
Signal transducer and activator of transcription 3 (STAT3)
is a member of the STAT family of transcription factors as
well as a critical molecule of JAK/STAT signaling pathway (2,
3). Deregulated STAT3 is oncogenic and has been shown to
be involved in the regulation of various important functions
such as cell proliferation, and differentiation in many cancer
cells. Constitutive and sustained activation of STAT3 has been
observed in many human malignancies including multiple
myeloma, leukemia, lymphoma, and solid tumors (4, 5).
Activation of STAT3 has been found to be associated with shorter
survival of patients with multiple myeloma (6). A number of
pro-survival and antiapoptotic genes are regulated by activation
of STAT3 at the transcription level including cyclin D, Bclxl,
Bcl2, survivin, MMP9, and VEGF (7, 8). Protein tyrosine
phosphatases (PTPs) are negative regulators of the JAK/STAT
signaling. SHP-1 is one of PTP members that has been shown
to dephosphorylate JAK kinases (9) and STAT3 directly (10) to
prevent the JAK/STAT pathway.
Sanguinarine (SNG) a benzophenanthridine alkaloid, said to
be a “secondary metabolite” or “natural product” (11, 12) is
predominantly isolated from the root of Sanguinaria canadensis
(13). In vivo and in vitro preliminary pre-clinical studies in
animal models have reported SNG anticancer potential via the
induction of apoptosis and/or anti-proliferative, anti-angiogenic,
and anti-invasive activity which has been well-documented in a
wide range of cancers (14–16) including lung (17–21), breast (22–
28) skin cancers (12, 29–32), and hematological malignancies
(33–38). Interestingly, SNG does not show toxicity in healthy
cells signifying its potential for anticancer agents (39). SNG
has been shown to induce cell death via the extrinsic and
intrinsic apoptotic pathways (14). Inhibition of more than 70%
of tumor growth has been seen via SNG-mediated production
of reactive oxygen species (ROS), inducing oxidative stress and
cell damage in cancer cells (16). In addition, SNG exhibits
cytotoxic effects via suppressing the activity of various signaling
cascades in a wide range of cancer cell lines (15, 31, 32,
40, 41). Although the anticancer activity of SNG has been
shown in hematological malignancies, mainly leukemias and
lymphomas but its anticancer potential has not been studied in
multiple myeloma.
In this study, we investigated the anticancer activity of SNG
in MM cell lines. Our data showed that SNG treatment of
MM cells suppressed the viability via induction of apoptosis.
SNG treatment of MM cells inactivated STAT3 activity with
concomitant upregulation of SHP-1, a PTPs that is a negative
regulator of STAT3. Furthermore, SNG-induced apoptosis
involves mitochondrial and caspase-cascade signaling pathway.
SNG mediated apoptosis was found to involve ROS due
to depletion of glutathione in MM cells. In addition, SNG
potentiated the anticancer effects of bortezomib in MM cell lines.
MATERIALS AND METHODS
Reagents and Antibodies
Sanguinarine chloride, Cell Counting Kit-8 (CCK-8), and
N-acetylcysteine (NAC) were purchased from Sigma Chemical
Co. (St. Louis, USA). Z-VAD-FMK was purchased from
Calbiochem (San Diego, USA). Antibodies against caspase-9,
Bclxl, Bcl2, phospho-STAT3, STAT3, SHP-1, cleaved caspase-3,
and caspase-3 were purchased from Cell Signaling Technologies
(Beverly, USA). VELCADE R© (Bortezomib), PARP, and GAPDH
antibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, USA). XIAP antibody was purchased from Abcam
(Cambridge, UK). FITC Annexin V apoptosis detection kit
I, Apo-Direct kit, Fixation/Permeabilization solution kit, BD
MitoScreen (JC-1), BV421mouse anti-γH2AX (pS139), PE rabbit
anti-active caspase-3, and Alexa Fluor 700 mouse anti-cleaved
PARP (Asp214) antibodies were purchased from BD Biosciences
(San Jose, USA). CellROXGreen and ThiolTracker Violet were
purchased from Invitrogen (Massachusetts, USA). RPMI 1640,
fetal bovine serum (FBS), Penicillin Streptomycin (PenStrep)
were purchased from Life technologies (California, USA).
Cell Culture
U266, MM1S, IM9, and RPMI-8226 cells were obtained from
ATCC, USA, and grown in RPMI 1,640 medium supplemented
with 10% (v/v) fetal bovine serum and 100 U/ml of Pen Strep at
37◦C in a humidified incubator with 5% CO2.
Cell Viability Assays
Briefly, 1 × 104 cells grown in 96-well cell culture plates (0.2mL
media) were treated with increasing doses of SNG. After the
incubation period (24 h), 10 µL of CCK-8 reagent was added to
the wells, followed by 2 h incubation at 37◦C. Finally, the optical
density was measured at 450 nm and percent cell viability was
calculated as described previously (42).
AnnexinV/propidium Iodide Dual Staining
U266, MM1S, and IM9 cell lines were treated with various doses
of SNG for 24 h. The cells were stained with annexin V-FITC and
propidium iodide as described earlier (42), and then analyzed by
flow cytometry.
Cell Lysis and Immunoblotting
SNG treated U266, MM1S, IM9, and RPMI cells were lysed with
Laemmli buffer as described previously (43), an equal quantity
of protein was separated by SDS-PAGE, transferred to PVDF
membrane, and then immunoblotted using various antibodies
and then visualized.
TUNEL Assay for Measurement of DNA
Double-Strand Breaks
DNA fragmentation in the MM cells was measured using
Apo-Direct kit as described earlier (44). Briefly, SNG treated
cells were initially fixed with 1% paraformaldehyde for 30min,
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permeabilized using ice-cold 70% ethanol, and then incubated
with 50 µL DNA labeling solution for 60min at 37◦C. Stained
cells were washed and then analyzed using LSRFortessa (Beckon
Dickinson, San Diego, USA).
Colony Formation Assay
Effect of SNG on the anchorage-independent growth of MM cells
was assayed by colony formation assay following the CytoSelect
96-well cell transformation assay kit’s protocol provided by the
manufacturer (Cell Biolabs, Inc.) Briefly, U266 and MM1S cell
lines were treated with SNG (0.25, 0.5, 1, 2, and 4µM) and
seeded in a density of 4 × 105 cell/ml into a 0.4% top agar layer
poured over 0.6% lower agar layer and incubated for 8 days at
37◦C and 5% CO2. Then agar was solubilized, and cells were
lysed. Following that, the CyQuant dye was used to measure the
fluorescence intensity of each well at 485/530 nm.
Comet Assay
The DNA damage in multiple myeloma cells was evaluated using
comet SCGE assay kit obtained from Enzo life sciences. The
multiple myeloma cells 1 × 105/ml at a ratio of 1:10 were mixed
with low melting agarose, and 75 µl of the mixture was added
to comet slide. The slides were kept in the dark for 10min and
then immersed in lysis solution followed by alkaline solution
and finally 1X TBE buffer. The slides were then transferred to a
horizontal gel electrophoresis apparatus, and power was supplied
at 1 volt per cm. Once electrophoresis was completed the slides
were dipped in 70% ethanol and air dried. Then 100 µl of diluted
CYGREEN R© nucleic acid dye was added to each circle of comet
slide and stained for 30min in the dark. The slides were dried
completely and visualized using epifluorescence microscopy.
Measurement of Active Caspase-3 and
Cleaved PARP by Flow Cytometry
U266, MM1S, and IM9 cells were treated with increasing
concentrations of SNG as described in the figure legend. The cells
were fixed and permeabilized using Fixation/Permeabilization
solution kit, according to the manufacturer’s protocol. 0.5 ×
106 cells in 1x Perm-Wash buffer were stained with BV605
tagged anti-active caspase-3 and AF700 tagged PARP cleaved
form antibodies (5.0 µl each) for 30min, washed twice and then
analyzed by flow cytometry using BD LSRFortessa analyzer as
described previously (42).
Measurement of Bax/Bcl2 by Flow
Cytometry
U266 cells were treated with SNG, fixed, and permeabilized
using Fixation/Permeabilization solution kit, according to the
manufacturer’s protocol. 0.5 × 106 cells in 1x Perm-Wash
buffer were stained with FITC tagged anti-bax and V450 tagged
Bcl-2 antibodies (5.0 µl each) for 30min, washed twice and
then analyzed by flow cytometry. Matched isotype control
was prepared for all treatment conditions. The Bax/Bcl-2 ratio
was determined by dividing the relative median fluorescence
intensity (MFI) of Bax staining by the relative MFI of Bcl-2
staining. Relative MFI was determined by subtracting the
MFI of the staining isotype control from the MFI of the
monoclonal antibody.
Measurement of Mitochondrial Membrane
Potential (MMP)
Effect of SNG on the MMP of MM cells was determined using
BD MitoScreen (JC-1) assay kit as described earlier (45). After
incubation with SNG, cells in 1x assay buffer were incubated with
JC-1 stain for 15min at 37◦C, washed and then analyzed by Flow
Cytometry, to quantify the reduction in red fluorescence.
Cytochrome C Release Assay
U266 cells were treated with SNG (1, 2, and 4µM) for 24 h
and then cytosolic as well as mitochondrial fractions were
isolated as described previously (46). Briefly, cells were harvested,
incubated in ice-cold hypotonic buffer and then homogenized by
passing through a 22-gauge needle (15–20 times). Mitochondrial
pellet and cytosolic fraction were obtained by differential
centrifugation. Twentymicrogram protein from the cytosolic and
mitochondrial fractions was separated by SDS-PAGE and then
immunoblotted using anti-cytochrome c antibody.
Gene Silencing of STAT3 Using Small Inference
RNA Technique
U266 cells (1 × 106) were transfected with STAT3 siRNA
[Cat 4390824, Life Technologies, California, USA)] and Control
siRNA (Cat no: 1027281, Qiagen) using 4D-NucleofectorTM
System (Lonza). After 48 h of incubation, cells were lysed and
immunoblotted with anti-STAT3 and other antibodies.
Measurement of Reactive Oxygen Species
MM cells, IM9, and U266, were exposed to various doses of
SNG for a period of 24 h. After incubation, cells were harvested,
washed, and then stained with CellROX Green reagent (5µM in
HBSS) for 30min at 37◦C. The stained cells were analyzed by
flow cytometry as described earlier (42) to quantify the levels of
reactive oxygen species.
Measurement of Reduced Glutathione
MM cells IM9 and U266 were exposed to increasing doses of
SNG for a period of 24 h. After incubation, cells were harvested,
washed and then stained with ThiolTracker Violet reagent (5µM
in HBSS) for 30min at 37◦C. The stained cells were analyzed by
flow cytometry as described earlier (42) to quantify the levels of
reduced glutathione.
Statistical Analysis
The significance of differences between different treatment
groups was determined by one-way ANOVA with Sidak post-hoc
test, performed using GraphPad Prism v7.0 (GraphPad Software
Inc, California, USA). Values of P < 0.001 were considered
statistically significant. ∗ denotes p < 0.001. In all figures, data
is expressed as the mean ± standard deviation (S.D), with the
vertical error bars denoting the S.D.
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RESULTS
Treatment of MM Cells With SNG Mediates
Cellular DNA Damage and Induces
Apoptosis
We first determined whether treatment of MM cells with SNG
induces cellular damage. To achieve this objective, U266, MM1S,
IM9, and RPMI-8226 cells were treated with an increasing
dose of SNG for 24 h and viability was determined by cell
viability assay using CCK-8 solution. As shown in Figure 1A,
SNG treatment of U266 and RPMI-8226 cells significantly
decreased MM cell viability in a dose-dependent manner when
treated with 0.25–4µM SNG, with the half maximal inhibitory
concentration (IC50) between 1 and 2µM. In the next series of
experiments, we determined whether inhibition of cell viability is
due to apoptosis, measurement of apoptosis was performed using
various assays, including annexin V-FITC/PI dual staining and
measurement of DNA fragmentation by TUNEL assay. Annexin
V-FITC/PI dual staining showed that U266 treated with 0.25,
0.5, 1, 2, and 4µM SNG had a dose-dependent increase in
apoptosis (Figure 1B). A similar pattern of apoptotic response
was observed in IM9 and MM1S cell lines (Figures 1B,C).
DNA ds breaks were measured by means of a TUNEL assay,
using the fragmentation marker dUTP. This was carried out on
U266 cells treated with 0.25, 0.5, 1, 2, and 4µM SNG, which
revealed 11% control cells containing DNA ds breaks with over
92% of cells containing ds breaks when treated with 1–4µM
SNG (Figure 1D). DNA ds breaks were further confirmed by
measuring the staining with p-H2X, a marker for DNA ds breaks
(Supplementary Figure 1A). In addition, SNG induced cellular
DNA damage in individual cells could be visually deduced by
a COMET assay which revealed significant DNA damage in a
dose-dependent manner (Figure 1E). Finally, we assessed the
effect of SNG on colony formation ability of MM cells. U266
and MM1S cell were treated with various doses of SNG and
seeded on agar using CytoSelect; Cell Biolabs assay kit. After
8 days of incubation, colonies were quantified as described in
material methods. Using a fluorescence plate reader (485/520 nm
filter set) according to the assay protocol. As shown in Figure 1F
and Supplementary Figures 1B,C, SNG treatment causes a dose-
dependent decrease in colony formation ability in both cell lines.
Caspases are proteolytic proteins that play an important
role in the cell death signaling pathway for rapid and efficient
apoptosis (47, 48). Our results showed that SNG treatment
resulted in the activation of caspase-9 followed by the final
executioner -caspase 3, leading to PARP cleavage in MM cells
(Figure 2A). In addition, we also determined activation of
caspase-3 and the subsequent PARP cleavage by flow cytometry
to confirm the role of caspase cascade in SNGmediated induction
of apoptosis. Treatment of MM cells with SNG up to 1µM
resulted in a dose-dependent increase in the cellular levels of
active caspase 3 and cleaved PARP in all cell lines (Figures 2B,C)
while reaching to a saturation level at 2 and 4µM of SNG
treatment condition. The involvement of caspase activation in
SNG mediated apoptosis was further proved by the observation
that pretreatment of MM cell with z- VAD-FMK, a universal
inhibitor of caspases resulted in abrogation of SNG-induced
apoptosis, caspase signaling, DNA damage, and cell viability
(Figures 2D–H and Supplementary Figures 2A–C). All of the
above-discussed data substantiate the role of caspase-mediated
signaling pathways in SNG-induced apoptosis in MM cells.
SNG Activates the Intrinsic Apoptotic
Pathway in Multiple Myeloma Cells
Members of the Bcl-2 family is known to regulate apoptosis by
keeping a balance between the levels of anti-apoptotic genes,
such as Bcl-2, Bclxl, and the pro-apoptotic molecules with
BH3-domain (Bax, Bak, etc.). Any deviation from this delicate
balance can lead to activation or inhibition of mitochondria-
mediated death pathway (49). Therefore, we sought to evaluate
the effect of SNG on the protein levels of the most important
members of the Bcl-2 family; Bax and Bcl-2, in U266 cells. As
shown in Figures 3A–C, SNG treatment resulted in a significant
decrease in Bcl-2 expression in a dose-dependent manner which
coincides with the increase in Bax. Densitometric analysis of
the blots and flow cytometry analysis of Bax and Bcl2 proteins
confirms the rise in the ratio of Bax to Bcl-2 protein levels
(Figures 3A–C), which is known to occur during mitochondria-
mediated apoptosis (50).
The permeability of the mitochondrial outer membrane, as
well as the proton gradient across the inner membrane, can
be affected by alterations in the Bax/Bcl2 ratio, which can lead
to the loss of membrane potential. So, we designed further
experiments to study MMP as well as the cytosolic release of
cytochrome c (normally sequestered within the mitochondria) in
various MM cell lines with and without SNG treatment. After
SNG treatment, the transmembrane potential in MM cells was
analyzed using JC1 dye by flow cytometry as depolarization is
associated with early stages of the apoptotic process. As shown
in Figure 3D, there was a significant (p < 0.001) depolarization
of the membrane in a dose-dependent manner in all the
MM cell lines. SNG treatment resulted in an increase in the
cytoplasmic level of cytochrome c with a concomitant decrease
in mitochondrial fractions (Figure 3E). Cytosolic cytochrome c
triggers downstream events in the apoptotic cascade, including
the activation of caspase cascade which is a hallmark marker of
programmed cell death (51).
SNG Promotes Oxidative Stress via ROS
Generation in Multiple Myeloma Cells
Oxidative stress results from an imbalance between ROS
production and the cells ability to scavenge them (52). ROS
are a group of highly reactive molecules responsible for
regulating normal cell proliferation and differentiation (53).
Under normal physiological conditions, ROS function as “redox
messengers” in low levels mediating the growth adaptation and
overall survival of the cell (54). However, the high level of
these free radical molecules mediates cellular DNA damage,
reduces normal MMP, and promotes cancer cell death. SNG
has been shown to act as a ROS inducer via increasing ROS-
related stress resulting in ROS-dependent apoptosis in cancer
cells (16). Thus, we had an interest in identifying if SNG
could induce ROS-dependent apoptosis specifically in MM
cells. Therefore, we measured oxidative stress in SNG treated
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FIGURE 1 | Effects of SNG on proliferation, and apoptosis in MM cells. (A) SNG inhibits the viability of MM cells. U266, IM9, MM1S, and RPMI cells were incubated
with 0.25, 0.5, 1.0, 2.0, and 4µM SNG for 24 h. Cell proliferation assays were performed using CCK-8 as described in Materials and Methods. The graph displays the
mean ± SD (standard deviation) of three independent experiments with replicates of six wells for all the doses. *p < 0.001. (B) SNG induces apoptosis in MM cell
lines. U266, IM-9, and MM1S cells were treated with 0.25, 0.5, 1.0, 2.0, and 4µM of SNG for 24 h and cells were subsequently stained with fluorescein-conjugated
annexin-V, PI, and subsequently analyzed by flow cytometry. (C) The graph displays the mean ± SD (standard deviation) of percentage of apoptotic cells (Early
Apoptosis + Late Apoptosis) of two independent experiments with replicates of three wells for all the doses. #p < 0.05, *p < 0.001. (D) SNG treatment induces DNA
fragmentation in MM cells. U266 and IM9 cells were treated with and without 0.25, 0.5, 1.0, 2.0, and 4µM of SNG as indicated for 24 h and cells were subsequently
stained using the APO-DIRECT kit (BD Biosciences) to measure fragmentation using TUNEL assay (terminal deoxynucleotidyltransferase dUTP nick end labeling) as
described in Materials and Methods and then analyzed by flow cytometry. The graph displays the mean ± SD (standard deviation) of three independent experiments
for all the doses. *p < 0.001. (E) SNG treatment induces DNA damage in MM cells. IM-9 and U266 cells were treated with and without 0.25, 0.5, 1.0, 2, and 4.0µM
of SNG as indicated for 24 h and cells were used to perform Comet assay to visual DNA fragmentation as described in Materials and Methods and then analyzed by
flow cytometry. (F) Antiproliferative effects of SNG on U266 and MM1S cells were analyzed by colony formation assay. U266 and MM1S cells were plated on
methyl-cellulose with 0.25, 0.5, 1.0, 2, and 4.0µM of SNG for 10 days. Colonies were stained with CyQuant dye and fluorescence intensity measured at 485/530 nm.
The graph displays the mean ± SD (standard deviation) of three independent experiments for all the doses. *p < 0.001.
U266 and IM9 cells using the fluorogenic probe CellROX
Green which emits a strong fluorescence (peak emission at
525 nm) when oxidized by ROS. U266 and IM9 cells were
treated with SNG for 24 h at various concentrations. SNG
treated MM cells showed a dose-dependent generation of
ROS at the cellular level (Figure 4A). Pretreatment of MM
cell with N-acetyl-L-cysteine (NAC) an inhibitor of ROS
generation abolished significantly SNG-mediated ROS in both
cell lines (Figure 4B). Glutathione (GSH) is key component
of cellular antioxidant defense mechanism and has a vital role
in many oxidative stress-related diseases, including cancer. In
the next experiment, we evaluated whether SNG treatment
of MM cells reduced GSH level in MM cells. As shown in
Figure 4C, SNG treatment of U266 and IM9 resulted in a dose-
dependent depletion of GSH which was statistically significant.
Furthermore, when the MM cells were pretreated with 10mM
NAC, the SNG mediated deletion of GSH in MM cells was
prevented (Figure 4D). We determined in the next series of
experiments whether SNG mediated generation of ROS is
involved in the activation of caspase-mediated apoptosis in
MM cells. U266 and IM9 cells were initially incubated with
10mM NAC, followed by SNG treatment for 24 h. As shown in
Figures 4E–G, pretreatment of MM cells with NAC prevented
apoptosis as well as caspase activity strongly indicating that
SNG mediated ROS is involved in the induction of apoptosis in
MM cells.
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FIGURE 2 | SNG mediated activation of caspase cascade in MM cells. SNG-induced activation of caspase-9, caspase-3, and cleavage of PARP in MM cells. (A)
U266 and MM1S cells were treated with and without 0.25, 0.5, 1.0, 2.0, and 4µM of SNG for 24 h. Cells were lysed and 50 µg of proteins were separated on
SDS-PAGE, transferred to PVDF membrane, and immunoblotted with antibodies against caspase-9, caspase-3, cleaved caspase-3, PARP, and GAPDH.
SNG–induced caspase-3 activation (B) and PARP cleavage (C) in MM cell lines. U266, IM9, and MM1S were treated with and without 0.25, 0.5, 1.0, 2.0, and 4µM of
SNG for 24 h and levels of active caspase-3 and cleaved PARP were determined by flow cytometry as described in Materials and Methods. The graph displays the
mean ± SD (standard deviation). *p < 0.001. (D) Effect of z-VAD-FMK on SNG-induced caspase cascade. U266 and MM1S cells were pre-treated with 20µM
z-VAD-FMK for 1 h and subsequently treated with 2µM SNG for 24 h. Cells were lysed and 50 µg of proteins were separated on SDS-PAGE, transferred to PVDF
membrane, and immunoblotted with antibodies against caspase-3, cleaved caspase-3, PARP, and GAPDH. (E) Effect of z-VAD-FMK on SNG-induced apoptosis.
U266 and MM1S cells were treated as described above and induction of apoptosis was measured using fluorescein-conjugated annexin-V and propidium iodide
staining and analyzed by flow cytometry. The graph displays the mean ± SD (standard deviation) of the percentage of apoptotic cells (Early Apoptosis + Late
Apoptosis). *p < 0.001. (F) Pre-treatment of z-VAD-FMK prevented SNG mediated caspase-3 activation and PARP cleavage. U266 and MM1S cells were treated as
described above and analyzed for active caspase-3 and cleaved PARP by flow cytometry. The graph displays the mean ± SD (standard deviation). *p < 0.001. (G)
Effect of z-VAD-FMK on SNG-induced DNA damage. U266 and MM1S cells were treated as described above and induction of DNA damage was visualized using
Comet assay. (H) Effect of z-VAD-FMK on SNG-mediated inhibition of cell viability. U266 cells were pretreated with 20µM Z-VAD-fmk for 1 h. Then cells were treated
with 2µM SNG 24h and cell viability assay deterimed by CCK-8 kit as described in Methods. The graph displays the mean ± SD (standard deviation). *p < 0.001.
SNG Suppresses JAK2/STAT3 Survival
Pathway in Multiple Myeloma Cells
STAT3 is known to mediate cell survival in many cancers,
and U266 cell line is reported to have constitutively activated
STAT3 pathway. So, we analyzed the effect of SNG on the
phosphorylation and activation of STAT3 inMM cells by treating
the cells with increasing concentrations of SNG for 24 h. SNG
treatment resulted in the dephosphorylation of STAT3, whichwas
completely abolished at concentrations 2 and 4µM (Figure 5A).
Then, we checked the effect of SNG on the total protein levels
of STAT3. As shown in Figure 5A SNG treatment did not show
any effects on total STAT3 proteins. STAT3 has been shown to
be regulated by no-receptor tyrosine kinase JAK2 (55). Thus,
we sought to find out whether SNG mediated suppression
of STAT3 is JAK2 dependent. As shown in Figure 5A, SNG
treatment of U266 cell causes dephosphorylation of JAK2without
affecting its protein level. Interestingly, SNG did not show any
effects on the phosphorylation of JAK1 as well as on p-STAT3-
ser727 in U266 cells (Supplementary Figure 3). To further
characterize the functional effects of SNG-mediated inhibition of
STAT3 activity (dephosphorylation), we investigated the STAT3
downstream target gene products including cyclin D, Bclxl, and
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FIGURE 3 | SNG-induced mitochondrial signaling pathways in MM cells. SNG treatment causes an alteration in Bcl-2 expression. (A) U266 cells were treated with
increasing doses of SNG for 24 h as indicated. After cell lysis, equal amounts of proteins were separated by SDS–PAGE, transferred to PVDF membrane and
immunoblotted with antibodies against Bax, Bcl-2, and GAPDH as indicated. (B) Data obtained from immunoblot analyses of Bax and Bcl-2. U266 cells were used to
evaluate effects of SNG on Bax/Bcl-2 ratio. Densitometric analysis of Bax and Bcl-two bands was performed using AlphaImager Software (San Leandro, CA, USA),
and data (relative density normalized to GAPDH) were plotted as Bax/Bcl-2 ratio. (C) U266 cells were treated with and without 0.25, 0.5, 1.0, 2.0, and 4µM of SNG
for 24 h and levels of Bax and Bcl-2 were determined by flow cytometry as described in Materials and Methods. The MFI values were used to calculate the Bax/Bcl-2
ratio, and the mean ± SD (standard deviation) is plotted in the graph. * p < 0.001. (D) SNG treatment causes the loss of MMP in MM cells. U266, IM9, and MM1S
cells were treated with indicated doses of SNG for 24 h. After JC1 staining, cells were analyzed by flow cytometry as described in Materials and Methods. The graph
displays the mean ± SD of three independent experiments. *p < 0.001. (E) The SNG-induced release of cytochrome c. U266 cells were treated with and without 1.0,
2.0, and 4.0µM SNG for 24 h. Cytoplasmic fraction was isolated as described in Materials and Methods. Cell extracts were separated on SDS-PAGE, transferred to
PVDF membrane, and immunoblotted with an antibody against cytochrome c and GAPDH.
XIAP that are involved in proliferation and growth of MM cells.
As shown in Figure 5A, SNG treatment of MM cells resulted in
decreased expression of cyclin D, with maximal effect observed
at the doses 2 and 4µM. Further, we studied the involvement of
other antiapoptotic proteins in SNG-induced apoptosis. X-linked
Inhibitor of Apoptosis protein (XIAP) over-expression (56, 57)
has been reported to correlate with the suppression of apoptosis
in many cancer cells (58), and it is the most promising target
of Inhibitor of Apoptosis proteins (IAPs) family which is also
selectively over-expressed in various cancers including MM (59–
62). In diagnosedMMpatients, XIAP expression level is high and
decreased XIAP expression correlates with the treatment efficacy
of chemotherapy and proteasome inhibitors (63). Therefore, we
determined the effect of SNG on MM cell lines. As shown
in Figure 5A, U266 cells had higher levels of XIAP in the
control as expected, but a dose-dependent decrease in XIAP
expression was seen upon treatment with SNG. To provide
direct evidence, whether STAT3 down-regulates antiapoptotic
proteins such as Bclxl, survivin and XIAP in U266 cells, we used
RNA interference to knock down STAT3 using siRNA against
STAT3. As shown in Figure 5B, STAT3-specific siRNA decreased
the protein levels of STAT3, which lead to down-regulation
of Bclxl, survivin, and XIAP, in the U266 cells. In addition,
gene silencing of STAT3 resulted in activation of the caspases,
−3 and −9 (Figure 5B). These results suggest that targeting
STAT3 signaling either with SNG treatment or gene silencing
with siRNA resulted in downregulation of antiapoptotic genes
and activation of caspases that lead to induction of apoptosis in
MM cells.
PTPs are negative regulators of the JAK/STAT signaling (64).
Therefore, we sought to determine whether SNG-induced de-
phosphorylation (inactivation) of STAT3 is involving PTPs. As
shown in Figure 5A SNG treatment upregulates the expression
of SHP-1 in a dose-dependent manner. Moreover, pretreatment
of U266 cells with sodium pervanadate, a PTP inhibitor
prevented SNG-mediated dephosphorylation (inactivation) of
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FIGURE 4 | SNG increases ROS generation in MM cells. (A) U266 and IM9 cells were treated with SNG for 24 h, and the cellular level of ROS was measured using
CellROX Green reagent by flow cytometry as described in Methods. The graph displays the mean ± SD (standard deviation) of ROS levels (fold change compared to
control) of three experiments *p < 0.001. (B) Effect of NAC on SNG-induced generation of ROS. U266 and IM9 cells were pre-treated with 10mM NAC, subsequently
treated with 2µM SNG for 24 h. CellROX assays were performed as described in Methods. The graph displays the mean ± SD (standard deviation) of ROS levels (fold
change compared to control) of three experiments *p < 0.001. (C) Effect of SNG on reduced glutathione levels in MM cell lines. U266 and IM9 cells were treated with
increasing doses of SNG for 24 h and levels of reduced glutathione were determined using ThiolTracker Violet reagent by flow cytometry. The graph displays the mean
± SD (standard deviation) of ThiolTracker Violet MFI (fold change compared to control) of three experiments. #p < 0.05, *p < 0.001. (D) NAC pre-treatment of MM
cell prevents SNG-induced glutathione depletion. U266 and IM9 cells were pretreated with 10mM NAC, subsequently treated with 2µM SNG as indicated for 24 h
and GSH content was determined by ThiolTracker Violet by flow cytometry. Bars represent mean ± SD (standard deviation), *p < 0.001. (E) Pre-treatment of MM cell
with NAC prevent SNG-induced apoptosis. U266 and IM9 cells were pretreated with 10mM NAC, subsequently treated with 2µM SNG as indicated for 24 h. The
cells were then stained with fluorescein-conjugated annexin-V, PI, and analyzed by flow cytometry. The graph displays the mean ± SD (standard deviation) of the
percentage of apoptotic cells (Early Apoptosis + Late Apoptosis). *P < 0.001. (F) Pre-treatment of MM cell with NAC prevent SNG induced PARP cleavage and
Caspase-3 activity. U266 cells were pretreated with 10 mM NAC, subsequently treated with 2µM SNG as indicated for 24 h and levels of active caspase-3 and
cleaved PARP were determined by flow cytometry as described in Materials and Methods. The graph displays the mean ± SD (standard deviation) *p < 0.001. (G)
Effect of NAC on SNG-induced caspase cascade. U266 and MM1S cells were pre-treated with 10mM NAC and subsequently treated with 2µM SNG for 24 h. Cells
were lysed and 50 µg of proteins were separated on SDS-PAGE, transferred to PVDF membrane, and immunoblotted with antibodies against caspase-3, cleaved
caspase-3, PARP, and GAPDH.
STAT3 (Figure 5C), suggesting the role of SHP-1 in SNG-
mediated STAT3 de-phosphorylation (inactivation).
SNG Treatment of MM Cells Prevents IL 6
Secretion and Inhibits IL6 Inducible STAT3
Activation
U266 and MM1S cells were treated with 1 and 2µM of SNG for
24 h. Secretion of IL6 in cell culture media was measured by a
Multiplexing kit as described in material and methods. As shown
in Figure 6A, the secretion level of IL6 is comparatively higher in
U266 as compared to MM1S confirming earlier findings by Lin
et al. (65). Interestingly, SNG treatment of MM cells prevented
the secretion of IL6 secretion into the media (Figures 6A,B).
IL-6 has been shown to activate STAT3. Hence, we checked
whether IL6 could induce phosphorylation of STAT3 ofMMcells.
U266 and MM1S cells were treated with 100 ng/ml of IL6 for
various time-periods. Treatment of MM cells with IL6 causes
time-dependent phosphorylation of STAT3 in both cell lines
(Figure 6C). Thymoquinone has been shown to prevent IL-6
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FIGURE 5 | SNG suppresses constitutively activated STAT3 signaling pathway. (A) U266 cells were treated with increasing doses of SNG for 24 h as indicated. After
cell lysis, equal amounts of proteins were separated by SDS–PAGE, transferred to PVDF membrane, and immunoblotted with antibodies of p-JAK2, JAK2, p-STAT3
(Try705), STAT3, SHP-1, Cyclin D, Bclxl, Mcl1, survivin, XIAP, and GAPDH. (B) Effect of Stat3 knock-down on total STAT3 levels and related proteins. U266 cells were
transfected with either control (100 pM) or STAT3 specific siRNA (50 or 100 pM). Cells extracts were separated on SDS-PAGE, transferred to PVDF membrane, and
immunoblotted with antibodies against STAT3, Bclxl, survivin, XIAP, caspase-3, and caspase-9. (C) Involvement of Tyrosine-protein phosphatase in SNG induced
reduction of Stat3 phosphorylation. U266 cells were treated with 2.0µM SNG in the absence or presence of various doses of sodium pervanadate for 4 h, cell
extracts were prepared, and Western blotting was performed using p-STAT3 and STAT3 as indicated.
inducible p-SAT3 in MM cells (66), we also analyzed whether
SNG can prevent IL6 mediated-STAT3 activation. As shown in
Figure 6D, pretreatment of MM cell with SNG prevented IL6-
mediated STAT3 phosphorylation suggesting that SNG Inhibits
IL6 inducible STAT3 activation (Figure 6D).
Combination of SNG and Bortezomib
Enhances Cytotoxicity in Multiple Myeloma
Cells
Bortezomib (BTZ) is a selective, first-in-class, FDA-approved
proteasome inhibitor for the treatment of MM patients (43).
However, the efficacy of BTZ is mostly constrained due to
the development of resistance (67) and relapse (68) which are
wide-spread. Many natural compounds have been shown to
potentiated the anticancer activity of bortezomib in vitro as
well in vivo (69, 70) therefore, we sought to determine whether
SNG can increase the anticancer effects of BTZ in MM cells
when used as a combination treatment. To this end, we treated
U266 cells with sub toxic doses of SNG (0.5µM) and BTZ
(5 nM) alone or in a combination of SNG and BTZ. As shown
in Figure 7, the combination of SNG and BTZ reduced cell
proliferation significantly (Figure 7A) as compared to SNG or
BTZ single treatment condition. In addition, this combination
dose was able to enhance cell death via activation of caspase−3
and PARP (Figures 7B,C).
DISCUSSION
Previous studies showed that Sanguinarine (SNG) prevented
carcinogenic activity in various types of cancer cell lines. The
major mechanisms of anti-cancer activity described for SNG
was its role in triggering intrinsic apoptosis, stimulating the
generation of reactive oxygen species (ROS), and inducing DNA
fragmentation (16, 71–73). However, SNG activity was not yet
defined in Multiple myeloma (MM). Multiple myeloma is a
slow proliferative B cell malignancy that leads to a buildup of
apoptosis-resistant plasma cells in the bone marrow (1, 74).
In the current study, we investigated the anticancer effect of
SNG in MM cells. We performed a panel of tests to define
the mechanism of activity of SNG in four MM cancer cell
lines. Our findings strongly showed that SNG suppressed MM
cells proliferation through the generation of apoptotic effects.
The evidence for proapoptotic activity of SNG was revealed by
increased annexin-V/PI positive cells, activation of caspase-3 and
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FIGURE 6 | SNG mediated inhibition of IL 6 secretion and IL 6 induced STAT3 activation in MM cells. U266 (A) and MM1S (B) cells were treated with increasing
doses of SNG for 24 h as indicated. The culture supernatant was used to estimate the levels of IL 6 (pg/ml) as described by cytokine measement kit. The graph
displays the mean ± SD (standard deviation) of three independent of for all the doses. *p < 0.001 (C) U266 and MM1S cells were serum satrved for 24 h and
subsequently treated with IL6 (100 ng/ml) for indicated time periods. After cell lysis, equal amounts of proteins were separated by SDS–PAGE, transferred to PVDF
membrane and immunoblotted with antibodies of p-STAT3 (Try705) and STAT3. (D) SNG inhibits IL6 induced STAT3 activation. U266 and MM1S cells were serum
sartved for 24 h, subsequently pretreated with 2.0µM SNG for 1 h and then stimulated with IL 6 (100µg/ml) for 30min. Cell extracts were prepared, and Western
blotting was performed using antibodies against p-STAT3 and STAT3 as described earlier.
cleavage of PARP in MM cells after SNG treatment. It is well-
known that the balance of pro-apoptotic (Bax) and anti-apoptotic
(Bcl-2) proteins of the Bcl-2 family, plays a role in the integrity
of the mitochondrial membrane (75). Bax has been shown
to antagonize Bcl-2 expression leading to an alteration of the
mitochondrial membrane permeability followed by activation of
caspases and apoptosis (76). We are showing that SNG treatment
enhanced the Bax/Bcl-2 ratio in a dose-dependent manner.
Indeed, SNG treatment induces an alteration of Bcl-2 expression
and enhancement of Bax levels resulting in a significant alteration
in mitochondrial membrane potential (MMP). Consequently,
we observed that treated MM cells presented an increase in
cytochrome c levels in their cytosolic fraction and a concomitant
loss in their mitochondrial fraction. One of the functions of
cytosolic cytochrome C is to interact with apoptotic protease-
activating factor-1 (APAF-1) and procaspase 9 in the presence
of ATP to form the multimeric complex, apoptosome, which in
turn activates caspase 9 and induce apoptosis (34). Since we show
that caspase 9 expression was efficiently increased in MM cells
in response to SNG treatment, we suggest that SNG-mediated
apoptosis in MM cell lines involves mitochondria-mediated
caspase activity. Moreover, SNG caspase-dependent apoptotic
effect was again confirmed by using z-VAD-FMK, a universal
inhibitor of caspases, which prevented SNG-mediated apoptosis.
ROS generation and resulting oxidative stress are associated
with cell death in many types of cells (30). In the present
study, we showed that SNG treatment significantly induced
the production of ROS along with a depletion of glutathione
(GSH) level in MM cells. Furthermore, pretreatment of MM
cells with N-acetylcysteine (NAC) seems to inhibit SNG-induced
proapoptotic effects including depletion of GSH, apoptosis and
activation of caspases and PARP. These findings strongly suggest
that SNG mediated proapoptotic effects in MM cells occurs
through the involvement of ROS.
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FIGURE 7 | SNG enhances the cytotoxicity of bortezomib in MM cells. (A) U266 cells were treated with 0.5µM SNG and 5 nM BTZ alone or in combination for 24 h
as indicated. Cell proliferation assays were performed using CCK-8 as described in Materials and Methods. The graph displays the mean ± SD (standard deviation) of
three independent experiments with replicates of six wells for all the doses. *p < 0.001. (B) U266 cells were treated with SNG and BTZ as indicated earlier. The cells
were then stained with fluorescein-conjugated annexin-V, PI, and analyzed by flow cytometry. (C) U266 cells were treated with SNG and BTZ as indicated earlier. Cells
were lysed and 50 µg of proteins were separated on SDS-PAGE, transferred to PVDF membrane, and immunoblotted with antibodies against caspase-3, cleaved
caspase-3, PARP, and GAPDH.
Recent studies showed that deregulated intracellular signaling
of the JAK/STAT3 pathway plays a role in the emergence
of resistance to apoptosis in many human malignancies (77).
Indeed, constitutive JAK/STAT and NF-κB signaling have been
linked with the pathogenesis of MM (78, 79) and activated STAT3
was shown to control the transcription of many antiapoptotic
genes such as Bcl2, survivin, and Bclxl (80, 81). Upregulation
of these antiapoptotic proteins causes sustained cell survival,
enhances cellular resistance to chemotherapy and suppresses
apoptosis (82). Our data showed that SNG treatment leads to
suppression of constitutive phosphorylation of STAT3 in MM
cells. In addition, we also demonstrated that SNG inhibited
the phosphorylation of JAK2, an upstream tyrosine kinase
that regulates the activation of STAT3 (83). Furthermore, we
observed that U266 cells treated with SNG had a downregulated
expression of cyclin D, a proliferative marker of MM cells. SNG
also suppressed the expression of antiapoptotic genes; survivin,
Bclxl, and Bcl2, in a dose-dependent manner. Interestingly, gene
knockout of STAT3 in U266 cells using specific STAT3 siRNA
abolished the expression of survivin, Bclxl, and XIAP as well as
activated caspase-9 and caspase-3.
Moreover, we investigated the effect of SNG on the SHP-
1 molecule, a Protein tyrosine phosphatases (PTPs) which
would regulate the activation of STAT3 (84). Our data showed
that SNG treatment upregulated SHP-1 and this effect was
concomitant with a decrease in phosphorylation of STAT3 in
MM cells. To further confirm the role of SHP-1 in STAT3
activation/phosphorylation, we used pervanadate, an inhibitor
of PTPs. In the presence of pervanadate, SNG treatment
failed to suppress the phosphorylation of STAT3. Finally, our
data shows for the first time, that SNG inhibits secretion
of IL6 by MM cells, and suppresses IL-6 mediated signaling
pathway in U266 cells. Interestingly, SNG also potentiated
the anticancer effects of bortezomib (BTZ) in MM cells
suggesting that SNG may be a novel therapeutic agent for
management of MM treatment alone or in combination with
other anticancer agents.
In summary, our study is the first one to define the
mechanism of activity of SNG in MM cells. We obtained
significant data that provides evidence about the cytotoxic
effect of SNG in this malignancy. Indeed, we showed that
SNG treatment triggered cytotoxic effects by inactivation of
JAK/STAT3 activity via suppression of anti-apoptotic genes
(schematically depicted in Figure 8). We have described
a novel mechanism of action of SNG by showing that
it upregulates SHP-1 protein and consequently inhibit
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FIGURE 8 | Schematic diagram of SNG mediated action in MM cells.
phosphorylation and activation of STAT3. In addition, we
showed that SNG caused activation of intrinsic apoptotic
pathways in MM cells and these findings are in concordance
with previous studies that described the same mechanism of
activity but in different types of tumor cells. Moreover, we
demonstrated that SNG induces anticancer activity in MM
cells by depletion of glutathione resulting in the generation
of ROS.
Most importantly, we observed that anti-cancer activity
of the chemotherapeutic drug bortezomib was enhanced
when combined with SNG treatment in MM cells. These
findings provide fundamental information for the design
and selection of combinatory therapeutic approach to
treat MM. The main mechanism of action described for
bortezomib in MM is proteasome inhibition which results in
endoplasmic reticulum stress-induced apoptosis, accumulation
of ROS, and deregulation of functional proteins (such
as IL-6, TNF-α, NF-κB) (85). We think that it would be
interesting to investigate the effect of SNG on some additional
functional protein such as NF-κB to understand how it
can potentiate the anti-cancer activity of BTZ. Currently,
our objective is to perform further studies in MM animal
models and in MM human samples for confirmation of
our findings and for a better understanding in vivo of the
link between the different signaling pathways affected by
SNG treatment.
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